Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment
Shots:
- Boehringer Ingelheim and Circle Pharma have entered into a new research collaboration and licensing agreement for developing FIC cyclin inhibitor for precision cancer treatment
- BI will target the proteins involved in uncontrolled growth of cancer cells because of mutations or amplifications in the genes encoding cell division
- Under the terms of agreement, Circle Pharma is entitled to receive upfront as well as development, regulatory & sales milestones of ~$607M
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim & Circle Pharma
Related News:- Boehringer Ingelheim Reports the P-III (FIBRONEER-IPF) Trial Data of Nerandomilast to Treat Idiopathic Pulmonary Fibrosis (IPF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
